Simultaneous optimization of potency, selectivity and physicochemical properties for cannabinoid CB(2) ligands.
1Department of Chemistry, Adolor Corporation, Exton, PA 19341, USA. kworm@adolor.com
Current Pharmaceutical Design
|October 29, 2009
Summary
Developing selective CB2 receptor agonists offers therapeutic potential for pain and inflammation by minimizing CNS side effects. Medicinal chemistry strategies enhance oral bioavailability and efficacy of these compounds.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Neuroscience
Background:
- Non-selective cannabinoid ligands produce diverse physiological effects, including pain relief and anti-inflammation.
- Undesirable central nervous system (CNS) side effects are associated with non-selective cannabinoid receptor activity.
- Selective targeting of the CB2 receptor over the CB1 receptor is a key strategy for developing novel therapeutics.
Purpose of the Study:
- To review literature on selective cannabinoid CB2 receptor agonists from 2007 to present.
- To highlight structure-activity relationships (SAR) and medicinal chemistry approaches.
- To focus on improving physicochemical properties, metabolic stability, and oral bioavailability.
Main Methods:
- Literature search for selective CB2 agonists published between 2007 and the present.
- Analysis of SAR and medicinal chemistry strategies employed.
- Evaluation of methods to enhance lipophilic ligand properties.
Main Results:
- Identification of diverse CB2 agonists with improved oral bioavailability.
- Demonstration of in vivo efficacy in rodent pain models.
- Successful application of early physicochemical filtering and metabolic stability screening.
Conclusions:
- Medicinal chemistry strategies can overcome challenges with lipophilic CB2 agonists.
- Targeting CB2 receptors offers a promising therapeutic avenue for inflammation and pain.
- Optimized CB2 agonists exhibit favorable pharmacokinetic profiles and in vivo activity.
Related Concept Videos
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...
01:25Drug-Receptor Bonds
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
01:29Drug-Receptor Interactions
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
02:18The Equilibrium Binding Constant and Binding Strength
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...